,
your personalized virtual assistant to find clinical trials. Go head, 
Mark Knapp, M.D.
Zangmeister Center/Mid Ohio Oncology HematologyColumbus, Ohio - 43219 (614-383-6686) |
- CLINICAL TRIALS 1
- CONDITIONS3
- INTERVENTIONS2
- SINCE2009
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
July 2009 - May 2016
Lymphoma
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
Placebo
Rad001
